Literature DB >> 16222426

Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.

V Kaasinen1, R P Maguire, H-P Hundemer, K L Leenders.   

Abstract

6-[18F]fluoro-L-dopa (FDOPA) is a common presynaptic dopaminergic tracer used in examinations by positron emission tomography (PET) for patients with Parkinson's disease (PD). The distinct metabolic covariance pattern in the uptake of [18F]fluorodeoxyglucose (FDG) can also be used to investigate PD pathology. Although the two tracers are widely used in PD research and clinical assessment, no thorough comparative studies of the tracers have been made. In this study, 25 PD patients were examined with FDOPA and FDG to investigate relationships and clinical correlates of metabolic and monoaminergic function in the Parkinsonian brain. A VOI (volume-of-interest) analysis was achieved by 3D spatial normalisation and fixed VOI-sets. The hemisphere ipsi- and contralateral to the predominant symptoms of PD was identified in each data set, and data across subjects were related using that laterality, rather than body side. Regional covariance patterns for FDOPA and FDG were derived from principal component analysis (PCA). The results demonstrated hemispheric asymmetries and sex-differences in the striatal FDOPA uptake, which were not seen with FDG. In addition, the PCA analysis identified a positive relationship between a major component in FDOPA uptake (associated with the striatal uptake) and an FDG component, which had positive loadings in the thalamus and the cerebellum. The subject scores for these components correlated positively, and both had a negative association with the clinical severity of the disease. The specific extrastriatal FDG covariance pattern contained the thalamus and the cerebellum, components of the previously reported PD related pattern, but not the striatum. The network correlated with both the severity of clinical symptoms of PD and the severity of nigrostriatal dopaminergic hypofunction. The results indicate that FDG PET, when combined with multivariate network analysis at group-level, can be used as an indicator of PD severity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222426     DOI: 10.1007/s00415-005-0993-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

Review 1.  Measurement of glucose consumption using [(18)F]fluorodeoxyglucose.

Authors:  Klaus Wienhard
Journal:  Methods       Date:  2002-07       Impact factor: 3.608

2.  Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region-of-interest data.

Authors:  D A Rottenberg; J R Moeller; S C Strother; V Dhawan; M L Sergi
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

3.  The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

Authors:  D Eidelberg; J R Moeller; V Dhawan; J J Sidtis; J Z Ginos; S C Strother; J Cedarbaum; P Greene; S Fahn; D A Rottenberg
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

4.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

Authors:  D J Brooks; E P Salmon; C J Mathias; N Quinn; K L Leenders; R Bannister; C D Marsden; R S Frackowiak
Journal:  Brain       Date:  1990-10       Impact factor: 13.501

5.  Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

Authors:  B J Snow; I Tooyama; E G McGeer; T Yamada; D B Calne; H Takahashi; H Kimura
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

6.  Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo.

Authors:  T Pohjalainen; J O Rinne; K Någren; E Syvälahti; J Hietala
Journal:  Am J Psychiatry       Date:  1998-06       Impact factor: 18.112

7.  Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

Authors:  E S Garnett; C Nahmias; G Firnau
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

8.  Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data.

Authors:  J R Moeller; S C Strother; J J Sidtis; D A Rottenberg
Journal:  J Cereb Blood Flow Metab       Date:  1987-10       Impact factor: 6.200

9.  The metabolic topography of parkinsonism.

Authors:  D Eidelberg; J R Moeller; V Dhawan; P Spetsieris; S Takikawa; T Ishikawa; T Chaly; W Robeson; D Margouleff; S Przedborski
Journal:  J Cereb Blood Flow Metab       Date:  1994-09       Impact factor: 6.200

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  11 in total

1.  VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES.

Authors:  Finbarr O'Sullivan; Mark Muzi; David A Mankoff; Janet F Eary; Alexander M Spence; Kenneth A Krohn
Journal:  Ann Appl Stat       Date:  2014-06-01       Impact factor: 2.083

2.  Dopaminergic correlates of metabolic network activity in Parkinson's disease.

Authors:  Florian Holtbernd; Yilong Ma; Shichun Peng; Frank Schwartz; Lars Timmermann; Lutz Kracht; Gereon R Fink; Chris C Tang; David Eidelberg; Carsten Eggers
Journal:  Hum Brain Mapp       Date:  2015-06-03       Impact factor: 5.038

Review 3.  Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.

Authors:  Shichun Peng; David Eidelberg; Yilong Ma
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

4.  Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease.

Authors:  Flavio Nobili; Dario Arnaldi; Claudio Campus; Michela Ferrara; Fabrizio De Carli; Andrea Brugnolo; Barbara Dessi; Nicola Girtler; Silvia Morbelli; Giovanni Abruzzese; Gianmario Sambuceti; Guido Rodriguez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-09       Impact factor: 9.236

5.  Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction.

Authors:  Jung-Lung Hsu; Tzyy-Ping Jung; Chien-Yeh Hsu; Wei-Chih Hsu; Yen-Kung Chen; Jeng-Ren Duann; Han-Cheng Wang; Scott Makeig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-17       Impact factor: 9.236

Review 6.  Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.

Authors:  Yilong Ma; David Eidelberg
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

7.  Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease.

Authors:  Valentina Berti; Cristina Polito; Silvia Ramat; Eleonora Vanzi; Maria Teresa De Cristofaro; Giannantonio Pellicanò; Francesco Mungai; Paolo Marini; Andreas Robert Formiconi; Sandro Sorbi; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

Review 8.  Recent advances in PET imaging for evaluation of Parkinson's disease.

Authors:  Chrissa Sioka; Andreas Fotopoulos; Athanassios P Kyritsis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

9.  Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum.

Authors:  Carsten Eggers; Frank Schwartz; David J Pedrosa; Lutz Kracht; Lars Timmermann
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

10.  Shape (but not volume) changes in the thalami in Parkinson disease.

Authors:  Martin J McKeown; Ashish Uthama; Rafeef Abugharbieh; Samantha Palmer; Mechelle Lewis; Xuemei Huang
Journal:  BMC Neurol       Date:  2008-04-16       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.